Please assess the completion status of the following clinical trial:

Trial Title: Mifepristone and Misoprostol Versus Misoprostol Alone for Mid-trimester Termination of Pregnancy (14 - 21 Weeks LMP): A Randomized-controlled Double-blinded Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 14 to 21 weeks gestation, based on menstrual history and clinical exam (with or without ultrasound)~* Meet legal criteria to obtain abortion~* Present with closed cervical os and no vaginal bleeding~* Live fetus at time of presentation for service~* Have no contraindications to study procedures, according to provider~* Be able to consent to procedure, either by reading consent document or by having consent document read to her~* Be willing to follow study procedures~Exclusion Criteria:~* Known previous transmural uterine incision~* Known allergy to mifepristone or misoprostol/prostaglandin or other contraindications to the use of mifepristone or misoprostol~* Any contraindications to vaginal delivery, including placenta previa~* Presentation in active labor (defined as moderate to severe contractions every 10 minutes or less)

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- mifepristone+misoprostol (Type: EXPERIMENTAL): 200 mg mifepristone followed by 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
- misoprostol (Type: EXPERIMENTAL): 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).